CCIA
CNCE

Campbell & Co Investment Adviser’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-40,358
Closed -$270K – 1061
2022
Q3 		$270K Buy
+40,358
New +$245K 0.06% 516
2021
Q1 		– Sell
-12,954
Closed -$164K – 643
2020
Q4 		$164K Buy
+12,954
New +$148K 0.1% 377

Other funds holding CNCE

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Campbell & Co Investment Adviser's CNCE Position: Q4 2022 in Review

Campbell & Co Investment Adviser sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 40,358 shares — an estimated $270K sold.

Campbell & Co Investment Adviser first reported a position in CNCE in Q4 2020 and held it in 2 quarters. The position peaked at $270K in Q3 2022. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

  • Campbell & Co Investment Adviser reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 40,358 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $270K.
  • Campbell & Co Investment Adviser first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Concert Pharmaceuticals, Inc. position peaked at $270K in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.